Cell & Gene: The Podcast
Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.
Episodes
88 episodes
Pioneering Next-Gen TCR Therapies in Solid Tumors with Neogene Therapeutics’ Carsten Linnemann, Ph.D.
Carsten Linnemann, Ph.D., CEO of Neogene Therapeutics and Head of Oncology Cell Therapy Clinical Development, AstraZeneca joins Cell & Gene: The Podcast’s Erin Harris to discuss T-cell receptor (TCR) therapies for solid cancers. They talk t...
•
Episode 87
•
14:18
Optogenetics for Vision Restoration with Ray Therapeutics' Paul Bresge
Ray Therapeutics' Co-Founder and CEO, Paul Bresge, joins Host Erin Harris to talk about optogenetics and how the company’s optogenetics approach differs from other gene therapies on the market developed to restore vision in retinal diseases lik...
•
Episode 86
•
22:00
A New Approach to Genome Engineering with Tessera Therapeutics' Dr. Michael Severino
Tessera Therapeutics' CEO, Dr. Michael Severino, joins Host Erin Harris to discuss Gene Writing, the biotech's genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Severino discusses ...
•
Episode 85
•
28:06
Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts
Allogene Therapeutics' EVP of R&D and CMO, Dr. Zachary Roberts, penned an original article for Cell & Gene titled, The Path Forward for CLL is Allogeneic. In his article, Dr. Roberts explains that chronic lymphocytic leukemia (CLL) is t...
•
Episode 84
•
25:13
CGT Regulatory Update and Outlook with Dark Horse Consulting's Kimberly Benton, Ph.D.
Applications (BLAs) of recent approvals and complete responses for novel products or rare diseases as well as BLAs currently under review. Benton shares information about FDA Draft Gudiances, including Platform Technology Designation Program fo...
•
Episode 83
•
27:58
Identifying Drug Development Opportunities for DMD with CureDuchenne
Debra Miller, CEO and Founder and Dr. Michael Kelly, Chief Scientific Officer at CureDuchenne talk to Host Erin Harris about the FDA approval for the expansion to the label indication for ELEVIDYS from Sarepta Therapeutics as well as how CureDu...
•
Episode 82
•
29:55
Tackling "The Delivery Problem" of Gene Editing-Based Medicines with Mammoth Biosciences' Lucas Harrington
Lucas Harrington, Co-Founder and Chief Scientific Officer of Mammoth Biosciences, joins Erin Harris to shed light on the biotech's proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-...
•
Episode 81
•
21:01
TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D.
KSQ Therapeutics' CSO, Micah Benson, Ph.D., joins Erin Harris to discuss how Tumor-Infiltrating Lymphocytes (TILs) as a treatment modality have the potential to treat a variety of solid tumor types. Benson explains KSQ's Phase 1/2 clinical stud...
•
Episode 80
•
35:30
Synthetic Biology and Programmable mRNA with Strand Therapeutics' Jake Becraft
Strand Therapeutics' CEO and Co-Founder Jake Becraft joins Erin Harris to discuss genetic regulation and how the company's programmable mRNA constructs combine genes for self-replication derived from RNA viruses with genetically programmed logi...
•
Episode 79
•
27:52
Developing an mRNA Therapy for DMD with Elixirgen Therapeutics' Aki Ko
Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of t...
•
Episode 78
•
14:52
The Current State of the Global Regulatory Landscape with ISCT's Dr. Bambi Grilley
Dr. Bambi Grilley is Professor of Pediatrics and the Director of Clinical Research and Early Product Development for the Center of Cell and Gene Therapy (CAGT) at Baylor College of Medicine AND she is Chief Regulatory Officer at ISCT. Dr. Grill...
•
Episode 77
•
25:21
Dr. Bruce Levine on ISCT and the Future of CAR-T
In anticipation of ISCT 2024 in Vancouver, Canada, Dr. Bruce Levine is back on Cell & Gene: The Podcast to share information about the event as well as his expertise on the future of CAR-T therapy for solid tumors, autoimmune disease, and m...
•
Episode 76
•
31:49
CGTs for HIV Suppression with Addimmune's Dr. Marcus Conant
Dr. Marcus Conant is CMO at Addimmune, a biotech startup developing a cell therapy for HIV that spun out of cell and gene therapy biotech American Gene Technologies (AGT). He spent his career on the front lines of HIV treatment and research and...
•
Episode 75
•
18:51
Inside BlueRock Therapeutics' Parkinson's Disease Trial with Dr. Ahmed Enayetallah
BlueRock Therapeutics' SVP Head of Development, Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 ...
•
Episode 74
•
29:39
Reducing the Disease Burden of AML with Vor Bio's Dr. Robert Ang
In 2021 on Episode 13, Vor Bio’s President and CEO, Dr. Robert Ang shared data about the company’s lead engineered hematopoietic cell (eHSC) product candidate. Dr. Ang is back to talk to Cell & Gene: The Podcast Host, Erin Harris, about how...
•
Episode 73
•
23:08
Reducing Toxicities in Allogeneic Cell Therapies with Orca Bio's Dr. Scott McClellan
Orca Bio's CMO, Dr. Scott McClellan, joins Erin Harris on this episode of Cell & Gene: The Podcast to discuss how and why toxicities continue to stymie allogeneic cell therapies. They cover Orca Bio's plan to potentially lowering the risk o...
•
Episode 72
•
19:37
Inside Cellular Rejuvenation Therapies for Age-Related Diseases with Life Biosciences' Sharon Rosenzweig-Lipson, Ph.D.
On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Life Biosciences' CSO, Sharon Rosenzweig-Lipson, Ph.D., about the Boston-based biotech's cellular rejuvenation therapies for the treatment of age-related diseases. They ...
•
Episode 71
•
17:17
The Future of Rare Diseases with The Jackson Laboratory’s Rare Disease Translational Center's Cat Lutz
Rare Disease Day is February 29, 2024, and in honor of this important day, Cell & Gene: The Podcast Host Erin Harris sits down with Jackson Laboratory’s (JAX) Rare Disease Translational Center (RDTC)'s VP, Cat Lutz. They discuss RDTC's miss...
•
Episode 70
•
27:31
Inside Yescarta's Reduced Median Turnaround Time with Kite, a Gilead company's Christopher McDonald
On this episode of Cell & Gene: The Podcast, Christopher McDonald, Global Head of Technical Operations at Kite, a Gilead company, talks to Host Erin Harris about Kite's recent FDA approval of manufacturing process change resulting in reduce...
•
Episode 69
•
20:48
Pricing, Value, And Access of CGTs With The Dedham Group's Jennifer Klarer, M.Sc.Eng.
The Dedham Group's Jennifer Klarer, M.Sc.Eng., Partner and Head of Cell & Gene Therapy, joins Erin Harris on this episode of Cell & Gene: The Podcast for a deep dive into pricing and value for CGTs. Klarer shares a detailed breakdown of...
•
Episode 68
•
37:17
Breaking Down Solid Tumors with Triumvira Immunologics' Dr. Paul Lammers
Paul Lammers, M.D., M.Sc., CEO of Triumvira Immunologics joins Cell & Gene: The Podcast to talk to Host Erin Harris about TAC, the company's proprietary T cell Antigen Coupler, which has both autologous and allogeneic approaches. They also ...
•
Episode 67
•
21:33
4 Keys to Allo in 2024 with Poseida Therapeutics' Kristin Yarema, Ph.D.
Kristin Yarema, Ph.D., CEO, Poseida Therapeutics sits down with Cell & Gene: The Podcast Host Erin Harris to discuss four of the biggest challenges the CGT sector faces when it comes to the development of off-the-shelf therapies. Kristin sh...
•
Episode 66
•
31:59
Cell Therapy For Corneal Endothelial Dystrophies With Aurion Biotech's Greg Kunst
For this third and final episode recorded at ARM's 2023 Meeting on the Mesa, Cell & Gene: The Podcast Host, Erin Harris, sat down with Greg Kunst, president, CEO, and Board member at Aurion Biotech. Listen in as they discuss the cell therap...
•
Episode 65
•
13:41
Overcoming the Limitations of CAR T-Cell Therapy with Vittoria Bio's Nick Siciliano, Ph.D.
Vittoria Biotherapeutics’ CEO, Nick Siciliano, joins Erin Harris on this episode of Cell & Gene: The Podcast to discuss the company's mission to expand the applications for CAR-based therapeutics by employing novel cell engineering and gene...
•
Episode 64
•
17:23
Gene Therapy Deals, Collaborations, & Partnerships with Astellas' Richard Wilson
Richard Wilson, Senior Vice President, Primary Focus Lead, Genetic Regulation at Astellas sat down with Cell & Gene: The Podcast's Erin Harris at ARM's 2023 Meeting on the Mesa to discuss the gene therapy deal making landscape as well as As...
•
Episode 63
•
25:02